Induction of the lysosomal apoptosis pathway by Inhibitors of the ubiquitin-proteasorne system

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1463-1469

  Berncltsson, Maria ^a   Beaujouin, Melanie ^b   Rickarclsom, Linda ^c   Havelka, Aleksandra Mandic ^a   Larsson, Rolf ^c   Westman, Jacob ^d   Liaudet Coopman, Emmanuelle ^b   Linder, Stig ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d Medchemcon ^*  (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Cathepsin D; Chemical biology; Ubiquitin isopeptidase

Indexed keywords

CATHEPSIN; CATHEPSIN D; ENZYME INHIBITOR; NSC 638646; NSC 687852; PEPTIDASE; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; UBIQUITIN ISOPEPTIDASE; UBIQUITIN ISOPEPTIDASE INHIBITOR; UBIQUITIN PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; CATHEPSIN B; CYSTEINE PROTEINASE INHIBITOR; PROTEASOME; UBIQUITIN;

APOPTOSIS; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYSOSOMAL MEMBRANE PERMEABILIZATION; LYSOSOME; LYSOSOME MEMBRANE; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DEGRADATION; CELL MEMBRANE POTENTIAL; CELL STRAIN K 562; DRUG ANTAGONISM; DRUG EFFECT; INTRACELLULAR MEMBRANE; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CATHEPSIN B; CATHEPSIN D; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; HUMANS; INTRACELLULAR MEMBRANES; K562 CELLS; LYSOSOMES; MEMBRANE POTENTIALS; MITOCHONDRIA; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 60549090636     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24004     Document Type: Article

References (40)

1. Tolcher AW. Mita M. Meropol NJ, von Mehren M, Patnaik A, Padavie K, Hiii M, Mays T, McCoy T, Fox NL, Haipem W, Corey A, et al. Phase I. pharmacokinetic and biologic correlative study of tnapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1, J Clin Oncol 2007;25:1390-5.
2. Guieciardi ME, Leist M, Gores GJ. Lysosotnes in cell death. Oncogene 2004;23:2881-90.
3. Yan S, Sanieni M. Sloane BF. Cathepsin B and human tumor progression. Biol Chem 1998;379:113-23.
4. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rev JM, Roger P. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000;291:157-70.
5. Roberg K, Kagedal K, Öllinger K, Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblasts. Am J Pathol 2002:161:89-96.
6. Cirman T, Oresic K, Mazovee GD, Turk V, Reed JC, Myers RM, Salvesen GS, Turk B, Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papainlike lysosomal eathepsins. J Biol Chem 2004;279:3578-87.
7. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
8. Groll M, Heineraeyer W, Jager S, Ullrich T, Bochtler M, Wolf DH, Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA 1999;96:10976-83.
9. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacv comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006;3:374-87.
10. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006;46:189-213.
11. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci USA 2005;102:192-7.
12. Hägg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, Shoshan M, Linder S. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002;20:253-9.
13. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during earlv apoptosis. J Pathol 1999;187:567-72.
14. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.
15. Lövborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R. Inhibition of proteasome activity, nuclear factor-KappaB tra nslocation and cell survival bv the antialcoholism drug disulfiram. Int J Cancer 2006;118:1577-80.
16. Rickardson L, Wickstrom M, Larsson R, Lovborg H. Image-based screening for the identification of novel proteasome inhibitors. J Biomol Screen 2007;12:203-10.
17. Foghsgaard L, Wissing D, Mauch D, Laderaann U, Bastholm L, Boes M, Elling F, Leist M, Jaattela M. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001;153:999-1010.
18. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ. Cathepsin B contributes to TKF-alphamediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000; 106:1127-37.
19. Krepela E, Vicar J, Cernoch M. Cathepsin B in human breast tumor tissue and cancer cells. Neoplasma 1989;36:41-52.
20. Cavallo-Medved D, Mai J, Dosescu I, Sameni M, Sloane BF. Caveo- lin-1 mediates the expression and localization of cathepsin B, pro-uro-kinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005; 118:1493-503.
21. Buttle DJ, Murata M, Knight CG, Barrett AJ. CA074 methyl ester; a proinhibitor for intracellular cathepsin B. Arch Biochem Biophs 1992;299:377-80.
22. Mullally JE, Fitzpatrick FA. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharmacol 2002;62:351-8. 6. Cirman T, Oresic K, Mazovee GD, Turk V, Reed JC, Myers RM, Salvesen GS, Turk B, Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papainlike lysosomal eathepsins. J Biol Chem 2004;279:3578-87.
23. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 2001 ;276:30366-73.
24. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, Huang CC, Kain SR. Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 1998;273:34970-5.
25. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jaattela M, Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 2003;197:1323-34.
26. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006;281:11923-32.
27. Crawford LI, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC. Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO. PS-341, and. MG-132. Cancer Res 2006:66:6379-86.
28. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006;66:10425-33.
29. Kim I, Kim CH, Kim JH, Lee J, Choi JJ, Chen ZA, Lee MG, Chung KC, Hsu CY, Ahn YS. Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp Cell Res 2004;298:229-38.
30. Leist M, Jaattela M. Triggering of apoptosis by cathepsins. Cell Death Differ 2001;8:324-6.
31. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res 2006;66:9235-44.
32. Shoshan MC, Linder S. Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opin Drug Me tab Toxicol 2008;4:273-80.
33. Fribiey A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-704.
34. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, Weber E, Leist M, Jaattela M. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 2004;64:5301-10.
35. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochira Biophvs Acta 2004;1695:189-207.
36. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001 ;21: 185-210.
37. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
38. Hideshima T. Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
39. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 2003;22:3356-66.
40. Zhang M, Pickart CM, Coffino P. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. EMBO J 2003;22:1488-96.